Allay Therapeutics Strengthens Advisory Boards
Allay Therapeutics, a clinical-stage biotechnology company specializing in innovative pain management solutions, has announced an exciting expansion of its Clinical and Scientific Advisory Boards. This move aims to bolster the company’s capabilities as it focuses on advancing ATX101, a promising clinical candidate designed to transform post-surgical pain relief.
Expanding Expertise in Pain Management
In its commitment to revolutionize post-surgical pain management, Allay Therapeutics has appointed nine distinguished experts in the fields of pain management, pharmacology, anesthesiology, and clinical research to provide strategic insights. These leaders will guide the company as it navigates the complexities of clinical trials and regulatory processes while embarking on a significant Phase 2B registration trial for ATX101.
Composition of the Advisory Boards
Allay’s expanded Clinical Advisory Board (CAB) includes renowned members such as Sabry Ayad, M.D., a professor known for his extensive work in anesthesiology; Ron Burch, M.D., Ph.D., who brings a wealth of experience from senior positions in biopharmaceutical companies; David Dalury, M.D., an orthopedic surgeon focused on knee and hip surgeries; Hemant Pandit, FRCS, D.Phil, an expert in arthroplasty and research; and Christine Sang, M.D., M.P.H., recognized for her leadership in anesthesia and pain research.
The Scientific Advisory Board (SAB) sees contributions from leading minds like Christine Allen, Ph.D., noted for her advancements in drug formulation; Joachim Kohn, Ph.D., who specializes in developing biomedical products; Louis Lazo Radulovic, Ph.D., M.P.H., an authority in pharmacokinetics; and Arthur Tipton, Ph.D., a pioneer of drug delivery innovations.
Insights from Leadership
Adam Gridley, Chief Executive Officer of Allay Therapeutics, emphasized the importance of these appointments: "We are thrilled to welcome such a talented group of physicians and scientists to our expanded boards. Their diverse experiences will offer valuable guidance as we work to bring our ultra-sustained analgesic, ATX101, to market." The expertise of these advisors will be pivotal in addressing the challenges of the clinical landscape and ensuring patient needs are met effectively.
Understanding ATX101
ATX101 is a novel investigational product utilizing bupivacaine, coupled with a biopolymer to provide prolonged pain relief following surgeries such as total knee arthroplasty. Its unique formulation allows for the delivery of sustained analgesic effects over several weeks, significantly enhancing patient recovery experiences. The simplicity of its application during surgery demands no specialized training, positioning it as a groundbreaking alternative to conventional pain management methods.
About Allay Therapeutics
Allay Therapeutics is dedicated to advancing pain management through innovative technologies. Its proprietary platform integrates validated non-opioid analgesics and biopolymers to create dissolvable solutions that offer targeted, long-lasting pain relief. With a passionate team in the San Francisco Bay Area and Singapore, Allay aims to redefine post-surgical recovery and improve the overall quality of life for patients worldwide.
Frequently Asked Questions
What is the focus of Allay Therapeutics?
Allay Therapeutics specializes in developing innovative pain management solutions, particularly through the drug candidate ATX101.
Who are the new members of the advisory boards?
Allay has appointed experts in pain management, orthopedics, drug delivery, and pharmacology to its Clinical and Scientific Advisory Boards.
What is ATX101?
ATX101 is a novel investigational product designed to provide weeks of pain relief after surgeries like knee replacements.
How does Allay plan to develop ATX101?
Allay is advancing ATX101 through clinical trials, particularly a Phase 2B registration trial, leveraging insights from its expanded advisory boards.
What is the vision of Allay Therapeutics?
Allay seeks to transform post-surgical pain management by providing long-lasting, effective, and non-opioid pain relief options for patients.
